Mutations: APP E693G (Arctic)
Modification: APP: Transgenic
Disease Relevance: Alzheimer's Disease
Strain Name: B6CBA-Tg(Thy1.2-hAPParc)
Genetic Background: C57BL/6-CBA
Availability: Available through Annica Rönnbäck
This transgenic mouse line expresses human APP with the Arctic mutation. Mutant human APP is expressed at about three-fold higher levels than endogenous murine APP. The mice develop an age-dependent progression of amyloid pathology that starts with intracellular Aβ accumulation. Around 7-9 months diffuse extracellular Aβ deposits develop in the subiculum and then spread to interconnected brain regions, such as the retrosplenial granular cortex, thalamus, and mammillary bodies by 12-15 months. Neuropathology is more severe in female mice than males, but males exhibit a similar spatiotemporal pattern of amyloid development (Rönnbäck et al., 2011).
Transgenic mice with human APP (isoform 695) bearing the Arctic APP mutation (E693G).
Available through Annica Rönnbäck.
- Rönnbäck A, Sagelius H, Bergstedt KD, Näslund J, Westermark GT, Winblad B, Graff C. Amyloid neuropathology in the single Arctic APP transgenic model affects interconnected brain regions. Neurobiol Aging. 2011 Aug 29; PubMed.
- Hedskog L, Pinho CM, Filadi R, Rönnbäck A, Hertwig L, Wiehager B, Larssen P, Gellhaar S, Sandebring A, Westerlund M, Graff C, Winblad B, Galter D, Behbahani H, Pizzo P, Glaser E, Ankarcrona M. Modulation of the endoplasmic reticulum-mitochondria interface in Alzheimer's disease and related models. Proc Natl Acad Sci U S A. 2013 May 7;110(19):7916-21. PubMed.
- Dehvari N, Mahmud T, Persson J, Bengtsson T, Graff C, Winblad B, Rönnbäck A, Behbahani H. Amyloid precursor protein accumulates in aggresomes in response to proteasome inhibitor. Neurochem Int. 2012 Apr;60(5):533-42. PubMed.